

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

November 4, 2020

Scrip Code: JYOTHYLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 023

Scrip Code: 532926

Dear Sir,

Sub: Outcome of the Board Meeting held on November 4, 2020

Further to our letter dated October 27, 2020 on the captioned subject, we wish to inform you that the Board of Directors of the Company at its meeting held today at 11:30 a.m. and concluded at 1:50 p.m., approved the Un-audited Financial Results on Standalone and Consolidated basis for the quarter and half year ended September 30, 2020 with Limited Review by the Statutory Auditors of the Company.


Accordingly, in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Un-audited Financial Results on Standalone and Consolidated basis for the quarter and half year ended September 30, 2020 accompanied with the Limited Review Report by the Statutory Auditors of the Company.

Also attached is the Press Release by the Company in respect of its performance during the quarter and half year ended September 30, 2020.

Kindly take the above on your record and disseminate the same for the information of investors.

Thanking you,
Yours faithfully,

For Jyothy Labs Limited
(Formerly known as Jyothy Laboratories Limited)



Shreyas Trivedi
Head – Legal & Company Secretary
Encl.: as above

Jyothy Labs Limited
(Formerly known as Jyothy Laboratories Limited)

CIN: L24240MH1992PLC128651

'Ujala House', Ramkrishna Mandir Road,
Kondivita, Andheri (East), Mumbai 400 059.

Tel: +91 022-6689 2800 | Fax: +91 022-6689 2805

info@jyothy.com | www.jyothy.com

Limited Review Report on Unaudited Quarterly and year to date Standalone Financial Results of Jyothy Labs Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**To the Board of Directors of
Jyothy Labs Limited**
(formerly known as Jyothy Laboratories Limited)

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Jyothy Labs Limited (formerly known as Jyothy Laboratories Limited) ('the Company') for the quarter ended 30 September 2020 and year to date results for the period from 1 April 2020 to 30 September 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W / W-100022


Sreeja Marar
Partner

Membership No: 111410
UDIN: 20111410 AAAAC07758

Mumbai
4 November 2020

Limited Review Report on Unaudited Quarterly and year to date Consolidated Financial Results of Jyothy Labs Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**To the Board of Directors of
Jyothy Labs Limited**

(formerly known as Jyothy Laboratories Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Jyothy Labs Limited (formerly known as Jyothy Laboratories Limited) ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2020 and year to date results for the period from 1 April 2020 to 30 September 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
 1. Jyothy Fabricare Services Limited
 2. Jyothy Kallol Bangladesh Limited
 3. Snoways Laundress and Drycleaners Private Limited
 4. Four Seasons Drycleaning Company Private Limited
 5. JFSL-JLL (JV)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SRM

B S R & Co. LLP

Limited Review Report on Unaudited Quarterly and Year to date Consolidated Financial Results of Jyothy Labs Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Jyothy Labs Limited

(formerly known as Jyothy Laboratories Limited)

6. The Statement includes the interim financial information/ financial results of four subsidiaries which have not been reviewed/audited, whose interim financial information/ financial results reflect total assets of Rs.1667 lacs as at 30 September 2020 and total revenue of Rs.118 lacs and Rs.344 lacs, total net loss after tax of Rs.69 lacs and Rs.53 lacs and total comprehensive loss of Rs.81 lacs and Rs.58 lacs for the quarter ended 30 September 2020 and for the period from 1 April 2020 to 30 September 2020, respectively, and cash outflows (net) of Rs.185 lacs for the period from 1 April 2020 to 30 September 2020, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W / W-100022



Sreeja Marar

Partner

Membership No: 111410

UDIN: 20111410AAAACP7138

Mumbai
4 November 2020

JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED)

(CIN : L24240MH1992PLC128651)

STATEMENT OF STANDALONE/CONSOLIDATED FINANCIAL RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

Registered Office: Ujala House, Ramakrishna Mandir Road, Kondivita, Andheri East, Mumbai 400059.

(Rs in lacs)

Particulars	Standalone						Consolidated											
	Quarter ended			Half year ended			Year ended			Quarter ended			Half year ended			Year ended		
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020						
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited						
Revenue from operations	49,964	42,868	46,421	92,832	87,585	1,66,538	50,449	43,290	47,485	93,739	89,738	1,71,117						
Other income	394	424	545	818	1,028	2,005	402	403	547	805	1,036	2,000						
Total Income	50,358	43,292	46,966	93,650	88,613	1,68,543	50,851	43,693	48,032	94,544	90,774	1,73,117						
Expenses																		
(a) Cost of materials consumed	21,169	16,004	17,797	37,173	33,961	69,230	21,301	16,068	18,037	37,369	34,421	70,194						
(b) Purchases of stock in trade	7,045	4,389	6,902	11,434	12,252	23,149	7,045	4,389	6,902	11,434	12,252	23,149						
(c) Changes in inventories of finished goods, stock in trade and work-in-progress	(1,977)	2,795	533	818	538	(3,178)	(1,962)	2,830	504	868	507	(3,251)						
(d) Employee benefits expense	5,872	5,141	5,210	11,013	10,228	20,032	6,154	5,485	5,679	11,639	11,171	21,933						
(e) Finance cost	286	509	593	795	1,201	2,478	520	645	823	1,165	1,623	3,288						
(f) Advertisement and sales promotion expense	2,983	1,976	2,747	4,959	6,083	11,993	3,001	1,992	2,820	4,993	6,190	12,271						
(g) Depreciation and amortisation expenses	1,934	1,872	1,883	3,806	3,727	7,573	1,339	1,307	1,308	2,646	2,557	5,292						
(h) Other expenses	5,985	4,739	5,324	10,724	10,062	20,328	6,173	4,880	5,678	11,053	10,776	21,713						
Total expenses	43,297	37,425	40,989	80,722	78,052	1,51,605	43,571	37,596	41,751	81,167	79,497	1,54,589						
Profit before tax and exceptional item	7,061	5,867	5,977	12,928	10,561	16,938	7,280	6,097	6,281	13,377	11,277	18,528						
Exceptional item (Note 2)	-	-	-	-	378	378	-	-	-	-	-	378						
Profit before tax	7,061	5,867	5,977	12,928	10,183	16,560	7,280	6,097	6,281	13,377	10,899	18,150						
Tax expenses																		
Current tax	995	825	655	1,820	1,269	790	1,267	1,096	922	2,363	1,802	1,892						
Deferred tax charge / (credit)	1,166	972	839	2,138	1,710	2,663	1,171	978	840	2,149	1,712	2,728						
	(171)	(147)	(184)	(318)	(441)	(1,873)	96	118	82	214	90	(836)						
Net Profit for the period	6,066	5,042	5,322	11,108	8,914	15,770	6,013	5,001	5,359	11,014	9,097	16,258						
Other Comprehensive Income																		
(a) Items that will not be reclassified to profit or loss	(64)	(47)	22	(111)	44	(422)	(64)	(47)	22	(111)	44	(437)						
(b) Tax (expense)/benefit on items that will not be reclassified to profit or loss	23	16	(7)	39	(15)	148	23	16	(7)	39	(15)	148						
(c) Items that will be reclassified to profit or loss	-	-	-	-	-	-	(12)	7	26	(5)	1	33						
Other Comprehensive Income for the period	(41)	(31)	15	(72)	29	(274)	(53)	(24)	41	(77)	30	(256)						
Total Comprehensive Income for the period	6,025	5,011	5,337	11,036	8,943	15,496	5,960	4,977	5,400	10,937	9,127	16,002						
Profit/(loss) attributable to :																		
Owners of Jyothy Labs Limited							6,256	5,229	5,571	11,485	9,492	17,027						
Non-Controlling Interest							(243)	(228)	(212)	(471)	(395)	(769)						
Other Comprehensive Income attributable to :																		
Owners of Jyothy Labs Limited							(50)	(26)	35	(76)	30	(253)						
Non-Controlling Interest							(3)	2	6	(1)	-	(3)						
Total Comprehensive Income attributable to :																		
Owners of Jyothy Labs Limited							6,206	5,203	5,606	11,409	9,522	16,774						
Non-Controlling Interest							(246)	(226)	(206)	(472)	(395)	(772)						
Paid up equity share capital (Face value of Re 1/- each)	3,672	3,672	3,672	3,672	3,672	3,672	3,672	3,672	3,672	3,672	3,672	3,672						
Other equity						70,656						1,19,192						
Earnings Per Share of face value Re 1/- each																		
Basic earnings per share (Rs)	1.65	1.37	1.45	3.02	2.43	4.29	1.70	1.42	1.52	3.13	2.58	4.64						
Diluted earnings per share (Rs)	1.65	1.37	1.45	3.02	2.43	4.29	1.70	1.42	1.52	3.13	2.58	4.64						
	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised						

Notes :

- The above unaudited financial results of the Company for the quarter and half year ended September 30, 2020 were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 04, 2020. These results have been subjected to limited review by the statutory auditors.
- Exceptional item includes one time expenses related to change in brand identity of the Company including its logo and name.
- The Company has changed its name from Jyothy Laboratories Limited to Jyothy Labs Limited with effect from July 11, 2019 pursuant to the change of name certificate issued by the Ministry of Corporate Affairs.
- Previous period / year's figures have been regrouped/rearranged wherever necessary.
- For more details on results, visit investor center section of the Company's website at www.jyothyilabs.com and financial result under corporates section of Stock Exchange's Website at www.nseindia.com and www.bseindia.com.

For and on behalf of the Board of Directors

Place: Mumbai
Date: November 04, 2020



M.R. Jyothy
Managing Director
DIN : 00571828

SKM

Jyothy

JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED)
STATEMENT OF STANDALONE/CONSOLIDATED FINANCIAL RESULTS

Notes :

6. Statement of Assets and Liabilities :-

(Rs in lacs)

Particulars	Standalone		Consolidated	
	As at September 30, 2020	As at March 31, 2020	As at September 30, 2020	As at March 31, 2020
	Unaudited	Audited	Unaudited	Audited
Assets				
Non-Current Assets				
Property, plant and equipment	27,822	26,999	31,278	30,536
Capital work in progress	983	2,374	1,001	2,450
Right-of-use assets	4,364	4,525	4,946	5,158
Goodwill	10,288	10,288	78,633	78,633
Other intangible assets	5,028	6,599	527	590
Financial assets				
Investment in subsidiaries	14,135	13,929	-	-
Other investments	3	3	3	3
Loans	955	919	1,127	1,088
Other financial assets	25	363	35	373
Deferred tax assets (net)	9,979	9,622	10,094	10,270
Income Tax assets (net)	992	992	1,149	1,235
Other non-current assets	7,818	8,393	7,819	8,412
	82,392	85,006	1,36,612	1,38,748
Current assets				
Inventories	23,260	22,259	23,482	22,507
Financial assets				
Trade receivables	12,187	11,956	12,447	12,238
Cash and cash equivalents	7,781	686	8,570	1,492
Bank balances other than cash and cash equivalents	3,214	1,321	3,553	1,402
Loans	425	671	55	55
Other financial assets	297	316	297	316
Other current assets	6,703	6,699	6,871	6,861
	53,867	43,908	55,275	44,871
Total Assets	1,36,259	1,28,914	1,91,887	1,83,619
Equity				
Equity Share Capital	3,672	3,672	3,672	3,672
Other Equity	81,692	70,656	1,30,601	1,19,192
Equity attributable to owners of Jyothy Labs Limited	85,364	74,328	1,34,273	1,22,864
Non-controlling interests	-	-	(3,384)	(2,912)
Total equity	85,364	74,328	1,30,889	1,19,952
Liabilities				
Non-Current liabilities				
Financial Liabilities				
Borrowings	-	-	-	27
Other financial liabilities	2,918	2,900	3,289	3,324
Provisions	5,714	5,288	5,981	5,552
Other non-current liabilities	266	303	266	303
	8,898	8,491	9,536	9,206
Current liabilities				
Financial Liabilities				
Borrowings	7,958	22,094	16,730	22,094
Trade payables				
Total outstanding dues of micro enterprises and small enterprises	2,040	1,023	2,065	1,058
Total outstanding dues of creditors other than micro enterprises and small enterprises	16,420	11,656	16,678	11,918
Other financial liabilities	4,274	3,715	4,630	11,718
Other current liabilities	8,471	5,314	8,488	5,349
Provisions	2,077	2,247	2,114	2,278
Current Tax liabilities (net)	757	46	757	46
	41,997	46,095	51,462	54,461
Total liabilities	50,895	54,586	60,998	63,667
Total equity and liabilities	1,36,259	1,28,914	1,91,887	1,83,619

For and on behalf of the Board of Directors

M.R. Jyothy
Managing Director
DIN : 00571828

Place: Mumbai
Date: November 04, 2020



JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED)
STATEMENT OF STANDALONE/CONSOLIDATED FINANCIAL RESULTS

Notes :

7 Statement of Cash Flow :-

(Rs in lacs)

Particulars	Half Year ended			
	Standalone		Consolidated	
	30.09.2020	30.09.2019	30.09.2020	30.09.2019
	Unaudited	Unaudited	Unaudited	Unaudited
A. CASH FLOWS PROVIDED BY/(USED IN) OPERATING ACTIVITIES:				
Profit before tax	12,928	10,183	13,377	10,899
Adjustments to reconcile profit before tax to net cash flows :				
Depreciation and impairment of property, plant and equipment	1,476	1,402	1,627	1,538
Depreciation of right-of-use assets	758	760	951	960
Amortisation and impairment of intangible assets	1,572	1,565	68	59
Lease rent income	(5)	(5)	-	-
Loss / (profit) on sale of fixed assets	(1)	-	(1)	2
Net change in fair value of financial assets measured at FVTPL	-	(10)	-	(11)
Profit on sale of current investments	-	(86)	-	(101)
Finance costs	795	1,201	1,165	1,623
Interest income	(193)	(122)	(175)	(112)
Share of (profit) / loss from investment in partnership firm	21	(2)	-	-
Unrealised Foreign exchange fluctuation Loss (net)	14	2	14	2
Investment subsidy income	(37)	(36)	(37)	(36)
Operating profit before working capital changes	17,328	14,852	16,989	14,823
Movements in working capital :				
Decrease / (increase) in loans	225	(69)	(20)	(47)
Decrease / (increase) in trade receivables	(244)	380	(223)	671
Decrease / (increase) in other financial assets	18	9	18	9
Decrease / (increase) in inventories	(1,001)	522	(975)	484
Decrease / (increase) in other assets	523	(470)	515	(566)
Increase/ (decrease) in trade payables	5,781	(1,127)	5,767	(1,198)
Increase/ (decrease) in other financial liabilities	551	(1,659)	626	(1,448)
Increase/ (decrease) in other liabilities	3,157	(616)	3,139	(591)
Increase / (decrease) in provisions	145	371	149	391
Cash generated from operations	26,483	12,193	25,985	12,528
Taxes paid (net)	(1,427)	(2,224)	(1,352)	(2,276)
Net cash generated from operating activities (A)	25,056	9,969	24,633	10,252
B. CASH FLOWS PROVIDED BY/(USED IN) INVESTING ACTIVITIES:				
Purchase of fixed assets including capital work-in-progress and capital advances	(890)	(1,844)	(930)	(1,951)
Proceeds from sale of fixed assets	14	13	16	28
Proceeds from sale of Mutual funds	-	30,248	-	31,093
Investment in Mutual funds	-	(30,650)	-	(31,170)
(Investment in)/ maturity proceeds from fixed deposit (net)	(1,581)	307	(1,838)	467
Withdrawal from /(Investment) in partnership firm (net)	(2)	57	-	-
Interest income received	66	101	36	97
Lease rent income	5	5	-	-
Net cash (used in) investing activities (B)	(2,388)	(1,763)	(2,716)	(1,436)
C. CASH FLOWS PROVIDED BY/(USED IN) FINANCING ACTIVITIES:				
Finance cost paid	(649)	(903)	(2,186)	(1,205)
Repayment of Debentures	-	-	(6,000)	-
Repayment of borrowing	(26,650)	(9,161)	(26,738)	(9,249)
Proceeds from borrowings	12,585	14,873	21,085	14,873
Payment of principal portion of lease liabilities	(859)	(819)	(1,000)	(1,035)
Dividend paid	-	(11,016)	-	(11,016)
Dividend tax paid	-	(2,264)	-	(2,264)
Net cash (used in) financing activities (C)	(15,573)	(9,290)	(14,839)	(9,896)
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	7,095	(1,084)	7,078	(1,080)
Cash and cash equivalents at the beginning of the year	686	6,684	1,492	7,323
Cash and cash equivalents at the end of the half year	7,781	5,600	8,570	6,243
Components of cash and cash equivalents				
Cash in hand	13	22	44	66
Balance with scheduled banks - Current account	7,768	5,578	7,970	5,692
- Deposit account	-	-	556	485
Cash and cash equivalents considered for cash flow statement	7,781	5,600	8,570	6,243

The above Statement of Cash flow has been prepared under the 'Indirect Method' as set out in Ind-AS 7, 'Statement of Cash flows'.

For and on behalf of the Board of Directors

M.R. Jyothy
Managing Director
DIN: 00571828

Place: Mumbai

Date: November 04, 2020



JYOTHY LABS LIMITED (FORMERLY KNOWN AS JYOTHY LABORATORIES LIMITED)
REPORTING OF SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES


(Rs in lacs)

Particulars	Consolidated					
	Quarter ended			Half Year ended		Year ended
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue :						
A. Fabric Care	17,102	14,221	19,371	31,323	38,026	70,800
B. Dishwashing	19,164	15,658	15,508	34,822	28,934	56,670
C. Household Insecticides	6,029	6,364	4,919	12,393	7,453	18,136
D. Personal Care	6,283	5,996	5,485	12,279	11,456	18,042
E. Laundry service	396	315	952	711	1,941	4,126
F. Others	1,475	736	1,250	2,211	1,928	3,343
Net Sales	50,449	43,290	47,485	93,739	89,738	1,71,117
Segment Results:						
Profit / (Loss) before tax and finance cost						
A. Fabric Care	3,771	3,153	4,130	6,924	7,806	14,253
B. Dishwashing	3,745	3,246	2,397	6,991	4,005	7,974
C. Household Insecticides	(341)	(197)	(287)	(538)	(805)	(1,644)
D. Personal Care	1,592	1,530	1,696	3,122	3,537	4,783
E. Laundry service	(380)	(414)	(307)	(794)	(532)	(1,015)
F. Others	(12)	24	36	12	(1)	(218)
Total	8,375	7,342	7,665	15,717	14,010	24,133
Less: (i) Finance cost	(520)	(645)	(823)	(1,165)	(1,623)	(3,288)
(ii) Other unallocable expenditure	(702)	(746)	(679)	(1,448)	(1,390)	(2,852)
(iii) Exceptional Item	-	-	-	-	(378)	(378)
Add: Unallocable Income	127	146	118	273	280	535
Profit Before Tax	7,280	6,097	6,281	13,377	10,899	18,150
Segment Assets :						
A. Fabric Care	30,314	32,317	31,322	30,314	31,322	30,746
B. Dishwashing	22,522	21,136	18,912	22,522	18,912	19,726
C. Household Insecticides	13,213	13,716	14,930	13,213	14,930	14,249
D. Personal Care	7,377	8,409	7,875	7,377	7,875	8,114
E. Laundry service	12,458	13,064	12,886	12,458	12,886	12,840
F. Others	1,640	1,473	1,779	1,640	1,779	1,557
G. Unallocated assets	1,04,363	98,943	1,10,714	1,04,363	1,10,714	96,387
Total	1,91,887	1,89,058	1,98,418	1,91,887	1,98,418	1,83,619
Segment Liabilities :						
A. Fabric Care	12,372	10,873	12,870	12,372	12,870	10,858
B. Dishwashing	13,946	11,634	9,745	13,946	9,745	9,080
C. Household Insecticides	6,617	5,486	4,308	6,617	4,308	5,011
D. Personal Care	4,903	4,735	4,346	4,903	4,346	3,402
E. Laundry service	1,385	1,321	1,535	1,385	1,535	1,422
F. Others	698	441	501	698	501	399
G. Unallocated liabilities	21,077	29,639	38,762	21,077	38,762	33,495
Total	60,998	64,129	72,067	60,998	72,067	63,667

Notes:

- Fabric Care includes fabric whitener, fabric enhancer, detergent powder and bar soap. Dishwashing includes dish wash bar, liquid, dish wash scrubber, dishwash steel scrubber and dishwash powder. Household Insecticides includes mosquito repellent coil, liquid and insect repellents sticks. Personal Care includes body soap, face wash, toothpaste, deodorants, talcum powder, after shave, hand wash, hand sanitizer and moisturiser. Laundry services includes drycleaning and laundry. Others includes incense sticks, toilet cleaner and floor cleaner.
- Based on the "management approach" as defined in Ind AS 108 - 'Operating Segments', the Chief Operating Decision Maker 'evaluates the Company's performance and allocate resources based on an analysis of various performance indicators by business segments and segment information is presented accordingly.
- Goodwill identifiable to operating segments are included in segment assets, however, where goodwill relates to multiple operating segments and it is not practicable to allocate between segments, it is included in unallocated assets.
- Finance cost is not allocated to any operating segments as the Company reviews the treasury and finance cost at the group level. Accordingly, borrowings are also considered in unallocated liabilities.

For and on behalf of the Board of Directors



M.R. Jyothy
Managing Director
DIN : 00571828

Place: Mumbai
Date: November 04, 2020



SRM



Jyothy labs

RESULTS FOR THE QUARTER ENDED 30 SEPTEMBER 2020

FOCUSSED EXECUTION DELIVERS HEALTHY GROWTH

Mumbai, 4 November 2020 Jyothy Labs Limited, one of the leading Indian FMCG companies announced today its financial results for the quarter ended 30 September 2020. The Company delivered sales of ₹ 504 crores, increase of 6.2% value growth (FMCG sales grew by 7.6% while volume grew by 8.5%) against the same period previous year.

The revival of the consumer sentiment has been reflected in the Company's performance across our brand portfolio. We have been focussing on volume led sales growth, brand building, product innovation and cost rationalisation measures leading to sustainable profitable growth.

There is strong demand acceleration in the General Trade and Ecommerce Platform while Modern Trade stores ('MT') and Canteen Stores Department ('CSD') operations are still facing issues on the ground.

With the company's dedicated strong distribution network, on ground sales teams and strong leadership, Jyothy Labs has been able to bounce back in the most strategic manner along with re-establishing and strengthening its brand identities.

Jyothy Labs has further boosted its promotional activities and media spends to support full business potential of its brands and distribution.

FINANCIAL HIGHLIGHTS (Q2FY2021 results over same period last year)

- Net Sales at Rs. 504 Crores, up by 6.2% (FMCG Sales Volume up by 8.5%)
- EBITDA improved from 16.6% to 17.3% at Rs. 87.4 Crores, up by 11.1%
- Net Profit at Rs. 60.1 Crores, increased by 12.2%.

FINANCIAL HIGHLIGHTS (H1FY2021 results over same period last year)

- Net Sales at Rs. 937 Crores, up by 4.5% (FMCG Sales Volume up by 7.3%)
- EBITDA improved from 16.1% to 17.5% at Rs. 163.8 Crores, up by 13.6%
- Net Profit at Rs. 110.1 Crores, increased by 21.1%.

SEGMENT PERFORMANCE

FABRIC CARE - Fabric Whitener, Fabric Enhancer, Bar Soap and Detergent Powder.

Fabric Care sales declined by 11.7% for Q2FY2021 and 17.6% for H1FY2021. The usage of Post Wash Category especially Ujala Fabric Whitener have seen sequential improvement every month and has reached pre-covid levels.



DISHWASHING - Dish Wash Bar, Liquid, Gel, Powder and Scrubbers.

Dishwashing sales increased by 23.6% for Q2FY2021 and 20.4% for H1FY2021 as in-home consumption has increased, resulting in increase in demand for our entire dishwash portfolio backed by greater emphasis on hygiene. Exo, India's first Anti-bacterial dishwash brand has seen a good growth with consumers both in urban and rural markets.

HOUSEHOLD INSECTICIDES - Mosquito Repellent Coil, Incense Sticks and Liquid Vaporizer.

Household Insecticides sales increased by 22.6% for Q2FY2021 and 66.3% for H1FY2021. This was as a result of consumers adopting a preventive approach towards health.

Maxo Genius India first Automatic Liquid Vaporiser Machine continues to register good growth given its unique offering.

PERSONAL CARE - Body Soap, Face Wash, Hand Wash, Sanitizer and Toothpaste.

Personal Care Sales have increased by 14.5% for Q2FY2021 and 7.2% for H1FY2021 over same period last year. Our Neem based Margo portfolio of Soaps, Facewash, Handwash and Sanitizers are positioned to witness strong demand as hygiene is of utmost importance for consumers. We continue to witness increase in demand especially of smaller SKU's leading to higher penetration with new users.

Commenting on the financial performance of Q2FY2021, Ms. M R Jyothy, Managing Director, Jyothy Labs Limited said "Every Crisis is an opportunity for a Company to recommit itself. Our focus on Execution combined with our portfolio comprising of daily use 'Essential Hygiene' has delivered strong sales and profitable growth.

The confidence of consumers, dedication of our employees and business partners strives us to do better and positions us to take advantage of our full business potential. The Company is well positioned and committed to deliver sustainable volume led profitable growth through focus on strengthening the overall franchise"

About Jyothy Labs Limited

Jyothy Labs Limited (JLL), one of the leading Indian FMCG Companies was founded in 1983 with a single brand 'Ujala' which has evolved into a multi brand, BSE & NSE listed Company involved in the manufacturing and marketing of products in fabric care, dishwash, mosquito repellent and personal care.

The Company has leading brands like Ujala, Maxo, Exo, Henko, Pril, Margo, Mr. White, T-Shine, Neem, Maya and More Light that are well-known and established brands in their respective categories. The Company also runs an organized laundry chain which provides 'World class laundry at affordable price at your doorstep' through its subsidiary 'Jyothy Fabricare Services Limited'.

For more information, please contact:

Aniket Singh Chandel Adfactors PR M: +91 9987572883 E-mail: aniket.chandel@adfactorsor.com	Priya Mishra Adfactors PR M: +91 9769994866 E-mail: priya.mishra@adfactorspr.com
---	---

